EADV 2025: Day 1 Recap

The first day of the European Academy of Dermatology and Venereology Congress is complete! Check out our day 1 recap below. To stay informed with the latest insights live from Paris, France, subscribe to receive our eNewsletters and follow Dermatology Times on LinkedIn, Facebook, and X.

POLL: Are You Attending the EADV Congress 2025?

Join Dermatology Times at the EADV Congress 2025 for expert insights and live updates from Paris, France.

Zasocitinib Shows Early DLQI Gains in Patients with Psoriasis

Benefits of zasocitinib on quality of life were observed as early as week 4 and sustained through week 12.

Bimekizumab Sustains PASI 0 in Nearly Half of Patients to Year 4

By blocking 2 key inflammation signals, research found bimekizumab may help keep both skin and joints healthier over time.

Povorcitinib Shows Sustained Efficacy in HS at 24 Weeks

STOP-HS1 and STOP-HS2 phase 3 trials showed nearly 60% of patients achieving HiSCR50 by week 24.

Three-Year Data Reinforce Long-Term Efficacy and Safety of Bimekizumab in Hidradenitis Suppurativa

UCB presented new long-term data demonstrating bimekizumab’s durable efficacy and a consistent safety profile over extended treatment.

Sanofi Announces Positive Phase 2a Results for Brivekimig in HS

Sanofi's brivekimig shows promising phase 2a results for hidradenitis suppurativa, offering hope for effective treatment options.

Celldex Reports Strong Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria Across IgE Subgroups

According to a poster, barzolvolimab achieved comparable improvements in weekly urticaria activity scores across lgE subgroups.

Global Study Links Atopic Eczema to Increased Risk of Suicidal Ideation

A new study links atopic dermatitis to increased suicidal ideation, highlighting the condition's severe psychological impact.

Oral IL-23 Blocker Shows Durable Psoriasis Control at 1 Year

The trial confirmed that icotrokinra’s efficacy is consistent with injectable IL-23 inhibitors while offering an oral option.

Icotrokinra Outperforms Deucravacitinib in Psoriasis Phase 3 Trials

Phase 3 ICONIC-ADVANCE data showed icotrokinra outperformed deucravacitinib in moderate to severe psoriasis.